近年来，生物制造的热度居高不下，作为新兴的战略性领域，生物制造因其创新性和对传 统生产方式的颠覆性，被视为新的增长点，有助于推动产业结构优化和经济模式的转变。 由药融圈&Synbio深波联合发起，药融圈产业研究院精心编纂的 《2025中国合成生物制造产业发 展白皮书》 （以下简称《研究报告》），已于8月1日 在Synbio China 第三届中国合成生物学"科 学家+企业家+投资家"博览会正式发布！ 领取方式： 关注本公众号，扫码添加下方微信获取 白皮书电子版 2025中国合成生物 制造产业发展白皮书 本白皮书介绍了生物制造的发展现状及趋势，分析了生物制造的产业链和重点应用方向， 并精选 出中国生物制造产业10大链主企业，整理了15家上市公司合成生物学布局方向以及20大热门品种 ，同时探讨了生物制造面临的挑战，最终提出了针对性的政策建议，供业内参考 。 添加请备注：单位+职位+姓名 封面一览 Synthetic Biology 深波 1 251 息息与人脉精准链接平台 一、 凯赛生物（688065）…………………………………………………………………………………………………………………………………………………… ...

【SynBioCon】 获悉， 近期， 对于提问：关于甲醇蛋白项目，公司曾表示预计会在去年年底前取得中试试验的最终结果，请问现在有结果了吗？根 据公司前期对该项目的调研，该项目的市场前景如何？如果未来顺利建成投产，是否会成为公司的重点核心项目之一？会显著提升公司市值吗？ 川宁生物 在投资者互动平台表示 ： 甲醇蛋白项目是公司重点推进的核心项目之一 ，目前该项目已根据下游客户反馈正在进行相关改进型实验。 甲醇蛋白具有广阔的工业化生产前景，甲醇蛋白是以甲醇为碳源， 通过培养微生物生产的单细胞蛋白 ，具有成本低、质量稳定可控等优点，也被认 为是食用和饲用蛋白的有效替代品。 针对问题：请问公司合成生物进展如何，营收占比多少，抗生素中间体价格有所回升吗？ 川宁生物答复道： 2025年前三季度整体收入4,880万元 ，占整体营业收入比重较小。目前公司硫氰酸红霉素和头孢类中间体价格维持稳定，青霉素 类中间体价格有些许恢复。 此外，还表示公司核心化工原材料已建立完善的供应链体系，对进口原材料的依赖程度较低，供应链安全可控。 /DT 合成生物与绿色生物制造 交流群/ 让专业的人聚在一起, 合成生物学与绿色生物制造产业同行❤️↓ ...

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry as of March 16, 2026 [1] Core Insights - The report emphasizes the importance of products with price leadership amid rising costs in the supply chain due to geopolitical tensions and policy changes affecting raw material prices [2] - The report highlights the significant price increases in pharmaceutical raw materials, particularly vitamins and amino acids, which have seen price increases of 40.54% and 84.66% respectively since the beginning of the year [2] - The report notes the approval of China's first invasive brain-machine interface, marking a significant milestone in the medical device sector [5] - The report indicates a strong trend in China's innovative pharmaceuticals going global, with a notable increase in licensing-out transactions [6] Summary by Sections 1. Supply Chain Dynamics - The report discusses the impact of rising prices in upstream chemical products on pharmaceutical raw materials, stressing that the ability to pass on these costs is crucial for maintaining profitability [2] - It mentions that 90% of monitored products have seen price increases, with the chemical product price index rising by 28.52% since the beginning of the year [2] 2. Market Trends in Disposable Gloves - The report details the price increases in disposable nitrile gloves and PVC gloves due to rising costs of raw materials like butadiene and acrylonitrile, which have increased by 84.43% and 47.30% respectively [3] - It notes that the domestic utilization rate for nitrile gloves has improved, and export prices have been rising since late 2025 [3] 3. Regulatory Environment - The report highlights the impact of dual-use item management on the pricing of key materials, creating significant price disparities between domestic and international markets [4] - It suggests that stricter controls on resources like rare earths could enhance the competitive advantage of domestic medical products [4] 4. Innovations in Medical Devices - The report discusses the approval of the brain-machine interface by the National Medical Products Administration, which is expected to open new market opportunities [5] - It outlines the potential for significant market growth in this area, given the high number of spinal cord injury patients in China [5] 5. International Expansion of Chinese Pharmaceuticals - The report notes that there have been 39 licensing-out transactions in the innovative drug sector, with upfront payments totaling approximately $2.953 billion [6] - It emphasizes that the trend of Chinese pharmaceuticals going global continues to strengthen, with a focus on small nucleic acid drugs and dual antibodies [7] 6. Stock Recommendations - The report recommends focusing on raw material suppliers with price leadership, such as Zhejiang Medicine and Chuan Ning Biological, and highlights companies like Inco Medical and Blue Sail Medical in the disposable glove sector [8] - It also suggests monitoring companies involved in the invasive brain-machine interface and small nucleic acid drugs, indicating potential for growth in these areas [8]

Core Insights - The 11th Bio-based Conference and Exhibition will be held in Shanghai from May 20-22, focusing on bio-based chemicals and materials, featuring 11 thematic forums, 7 concurrent activities, and 1000 new product displays [2] Group 1: Company Overview - Kasei Biotech, established in 2000, focuses on synthetic biology and bio-manufacturing technology, becoming a global leader in producing new bio-based materials [3] - Kasei Biotech's revenue for 2025 is projected to reach 3.295 billion yuan, marking an 11.41% increase, with a net profit of 566 million yuan, up 15.7% [3] - Huaheng Biotech, founded in 2005, plans to list in Hong Kong and expects a revenue of 2.885 billion yuan in 2025, a 32.5% increase, but a net profit decrease of approximately 30% [9][10] - Huadong Medicine achieved a revenue of 41.906 billion yuan in 2024, a 3.16% increase, with a net profit of 3.512 billion yuan, up 23.72% [14] Group 2: Main Business Composition - Kasei Biotech's main revenue sources include long-chain dicarboxylic acids (2.67 billion yuan, 90.26% of revenue) and bio-based polyamides (144 million yuan, 4.88% of revenue) [6] - Huaheng Biotech's main products include amino acids (1.509 billion yuan, 69.29% of revenue) and vitamins (207 million yuan, 9.49% of revenue) [10] - Huadong Medicine's industrial microbiology segment saw revenue growth from 510 million yuan in 2022 to 711 million yuan in 2024, with a CAGR of 18.07% [14] Group 3: Research and Development Projects - Kasei Biotech is investing in projects like bio-manufacturing research with a total investment of 6.3 million yuan, focusing on fermentation and extraction technology [7] - Huaheng Biotech has multiple ongoing projects, including optimizing amino acid production strains and developing high-purity amino acid removal processes [11][12] - Huadong Medicine has initiated 393 research projects in industrial microbiology, focusing on xRNA raw materials and health-related products [18] Group 4: Development Strategies - Kasei Biotech aims to expand large-scale applications of bio-materials to replace petrochemical products and utilize agricultural waste for bio-manufacturing [8] - Huaheng Biotech focuses on becoming a leader in synthetic biology through innovation and collaboration, emphasizing the use of renewable resources [13] - Huadong Medicine is accelerating its business layout through cooperation and acquisitions, focusing on xRNA raw materials and health products [25] Group 5: Financial Performance - Kasei Biotech's revenue for 2025 is projected to be 3.295 billion yuan, with a net profit of 566 million yuan [3] - Huaheng Biotech expects a revenue of 2.885 billion yuan in 2025, with a significant decrease in net profit [9] - Huadong Medicine's revenue reached 41.906 billion yuan in 2024, with a notable increase in net profit [14] Group 6: Market Trends - The bio-based industry is witnessing a shift towards sustainable materials, with companies focusing on reducing reliance on fossil fuels and enhancing the use of agricultural by-products [8][13] - The demand for bio-based products is expected to grow, driven by environmental concerns and regulatory support for sustainable practices [2][8]

Core Insights - The 11th Bio-based Conference and Exhibition will be held in Shanghai from May 20-22, focusing on bio-based chemicals and materials, featuring 11 thematic forums, 7 concurrent activities, and 1000 new product displays [2] - The article outlines the basic information, main business composition, ongoing projects, and development strategies of ten leading companies in the bio-manufacturing industry, including Kasei Biotech, Huaheng Biotech, and others [2] Group 1: Kasei Biotech (688065) - Kasei Biotech achieved a revenue of 3.295 billion yuan in 2025, marking an 11.41% year-on-year increase, with a net profit of 566 million yuan, up 15.7% [3] - The main business composition includes synthetic bio-materials, with long-chain dicarboxylic acids generating 2.67 billion yuan in revenue, accounting for 90.26% of total income [6] - Ongoing projects focus on bio-manufacturing research, including the development of fermentation technology for bio-based materials and high-throughput microbial screening systems [7][8] Group 2: Huaheng Biotech (688639) - Huaheng Biotech plans to list in Hong Kong, with projected revenue of 2.885 billion yuan in 2025, a 32.5% increase, but a net profit decrease of approximately 30% [9][10] - The main business composition includes amino acids, contributing 1.509 billion yuan, and vitamins, contributing 207 million yuan, with a significant portion of revenue coming from overseas [11] - Ongoing projects include optimizing amino acid production strains and developing high-purity amino acid removal processes [12][13] Group 3: Huadong Medicine (000963) - Huadong Medicine expects a revenue of 41.906 billion yuan in 2024, a 3.16% increase, with a net profit of 3.512 billion yuan, up 23.72% [15] - The industrial microbiology segment saw revenue growth from 510 million yuan in 2022 to 711 million yuan in 2024, with a CAGR of 18.07% [15] - The company has initiated 393 research projects in the industrial microbiology field, focusing on xRNA materials and health-related products [19] Group 4: Meihua Biotech (600873) - Meihua Biotech reported a revenue of 25.069 billion yuan in 2024, a 9.69% decrease, with a net profit of 2.740 billion yuan, down 13.85% [28] - The company focuses on amino acid production and has developed a comprehensive ecosystem including animal nutrition and pharmaceutical-grade amino acids [27] - Research and development investments reached 733 million yuan in 2024, emphasizing the development of new technologies and strains [31] Group 5: Chuan Ning Biotech (301301) - Chuan Ning Biotech achieved a revenue of 5.758 billion yuan in 2024, a 19.38% increase, with a net profit of 1.400 billion yuan, up 48.88% [36] - The main business composition is primarily in pharmaceutical manufacturing, with a significant portion of revenue from pharmaceutical intermediates [38] - The company has established a commercial system integrating product selection, research, and large-scale production [37]

Core Viewpoint - The article emphasizes the rising importance of biomanufacturing as a strategic and innovative field that disrupts traditional production methods, presenting it as a new growth point for optimizing industrial structure and transforming economic models [1]. Group 1: Current Status and Trends - The "2025 China Synthetic Biomanufacturing Industry Development White Paper" was officially released on August 1, highlighting the current state and trends of biomanufacturing [1]. - The report analyzes the global biomanufacturing industry, including key platform facilities and a comparative study of the US and China in this sector [7]. Group 2: Policy Landscape - The white paper outlines major domestic and international policies affecting biomanufacturing from 2024 to 2025, providing insights into regulatory frameworks [7]. Group 3: Industry Map and Applications - It presents a comprehensive map of the Chinese biomanufacturing industry and identifies key application areas, including pharmaceuticals, food, personal care, agriculture, chemicals, materials, and energy [7]. Group 4: Key Enterprises - The report selects ten leading enterprises in the Chinese biomanufacturing sector and details the strategic directions of 15 listed companies in synthetic biology [7][8]. Group 5: Investment and Challenges - The document discusses the investment landscape in synthetic biology from 2024 to mid-2025 and addresses the challenges faced by the biomanufacturing industry in China, along with proposed countermeasures [7].

Core Viewpoint - The report highlights the growth of industrial enterprises in the Xinjiang Uygur Autonomous Region, indicating a significant increase in the number of large-scale industrial companies and their contribution to the national economy [1]. Group 1: Industrial Growth in Xinjiang - As of January to December 2025, the number of industrial enterprises in Xinjiang is projected to be 5,576, which represents an increase of 438 enterprises compared to the previous year, marking a year-on-year growth of 8.52% [1]. - The industrial enterprises in Xinjiang account for 1.06% of the total number of such enterprises in the country [1]. Group 2: Industry Research and Consulting - Zhiyan Consulting is recognized as a leading industry consulting firm in China, specializing in deep industry research and providing comprehensive consulting services, including industry research reports and feasibility studies [1]. - The firm emphasizes its commitment to delivering high-quality services and market insights to empower investment decisions [1].

Core Viewpoint - The AI medical sector experienced a decline of 0.66% on February 11, with QianYuan Pharmaceutical leading the drop. The Shanghai Composite Index rose by 0.09%, while the Shenzhen Component Index fell by 0.35% [1]. Group 1: Market Performance - The closing price of QianYuan Pharmaceutical was 11.44, down by 4.67%, with a trading volume of 209,800 shares and a transaction value of 243 million [2]. - The AI medical sector saw a net outflow of 1.345 billion from major funds, while retail investors contributed a net inflow of 1.14 billion [2][3]. Group 2: Individual Stock Performance - YoukeDe (688158) closed at 37.54, up by 5.12%, with a trading volume of 631,000 shares and a transaction value of 2.36 billion [1]. - AidiTe (301580) closed at 55.18, up by 4.63%, with a trading volume of 46,100 shares and a transaction value of 251 million [1]. - SanNuo Biology (300298) closed at 18.54, up by 2.71%, with a trading volume of 105,200 shares and a transaction value of 194 million [1]. - The top decliners included QianYuan Pharmaceutical (300254) and KaiPu Biology (300639), with declines of 4.67% and 4.23%, respectively [2].

Summary of Industry Reports Industry: Pharmaceutical and Biotechnology Key Points from Document 1 1. **Raw Material Supply Changes**: The supply of raw materials is accelerating, with a focus on subsequent volume and price changes [1] 2. **Global GLP-1 Landscape**: The global GLP-1 landscape is continuously evolving, and Chinese companies are still pursuing international expansion [1] 3. **Small Nucleic Acid Sector**: Leading companies are gradually entering the small nucleic acid field, with market progress expected to drive the development of supporting industrial chains [1] 4. **Retail Pharmaceutical Market Outlook**: The retail pharmaceutical market is expected to improve by Q4 2025, with an enhanced positioning of chain pharmacies [1] 5. **Value of Oral Immunomodulatory Drugs**: Emphasis on the market value of oral immunomodulatory drugs [1] 6. **Investment Recommendations**: Recommended companies include Chuaning Biological, with attention to Lianbang Pharmaceutical, Guobang Pharmaceutical, and Puluo Pharmaceutical, as well as synthetic biology companies [1] 7. **CXO Order Trends**: Positive trends in CXO orders and rising prices for safety evaluation orders, with recommendations for Yinos and Zhaoyan New Drug, and recommendations for Weiya Biological and Puris [1] Key Points from Document 2 1. **Small Nucleic Acids Breakthrough**: Continuous breakthroughs in small nucleic acids, with ongoing progress in external authorizations by Chinese companies, recommending Yuekang Pharmaceutical and Sunshine Novo [2] 2. **Self-Immunity Field**: Focus on breakthroughs in oral directions and difficult-to-treat areas like UC/IBD, recommending Yahong Pharmaceutical and Yifang Biological [2] 3. **GLP-1 Weight Loss Authorizations**: Recommendations for Zhongsheng Pharmaceutical in the GLP-1 weight loss field, with attention to Lianbang Pharmaceutical and Shiyao Group [2] 4. **ZAP-X Radiation Therapy Equipment**: Initiation of domestic clinical research for ZAP-X radiation therapy equipment, recommending Baiyang Pharmaceutical [2] 5. **Policy Support for Brain-Computer Interface Technology**: Support for the development of invasive brain-computer interfaces, recommending Meihao Medical and Botuo Biological, with accelerated approvals for non-invasive devices, focusing on Xiangyu Medical and Kefu Medical [2] 6. **High-Value Medical Device Exports**: Breakthroughs in exports of high-value medical consumables, with attention to Chunli Medical, Aikang Medical, Nanwei Medical, and Baixin An [2] 7. **AI in Healthcare**: Accelerated applications of AI in healthcare, reshaping application scenarios and bringing changes in industrial chain value, recommending Anbiping and focusing on Yuyue Medical and Meinian Health [2] 8. **Chain Pharmacy Industry**: Industry consolidation in chain pharmacies, with policy support for enhanced positioning, recommending Yifeng Pharmacy and Laobaiqing, with attention to Yixintang [2]

Market Overview - The corn concept sector declined by 0.14%, ranking among the top losers in the market, with *ST Wanfang hitting the limit down, while COFCO Technology, Xiamen Xiangyu, and Beidahuang also saw significant declines [1] - In contrast, 15 stocks within the sector experienced price increases, with Fucheng Co., Chuaning Bio, and Yasheng Group leading the gains at 2.40%, 1.97%, and 1.67% respectively [1] Sector Performance - The top-performing concept sectors included BC batteries (+8.56%), perovskite batteries (+8.24%), and TOPCON batteries (+7.39%), while the soybean sector fell by 0.10% [1] - The corn sector saw a net outflow of 0.96 billion yuan, with 16 stocks experiencing net outflows, and 7 stocks seeing outflows exceeding 10 million yuan [1] Fund Flow Analysis - Beidahuang led the net outflow with 28.21 million yuan, followed by Shennong Seed Industry and Yuntu Holdings with outflows of 23.43 million yuan and 22.67 million yuan respectively [1] - Conversely, the stocks with the highest net inflows included Xinghuo Technology, Fucheng Co., and Jinjian Rice Industry, with inflows of 18.68 million yuan, 12.25 million yuan, and 12.10 million yuan respectively [1][2] Individual Stock Performance - Beidahuang's stock price decreased by 1.52% with a turnover rate of 1.64% and a net outflow of 28.21 million yuan [1] - COFCO Technology and *ST Wanfang also saw declines of 2.59% and 5.09% respectively, with net outflows of 5.94 million yuan and 5.90 million yuan [2] - On the other hand, stocks like Fucheng Co. and Xinghuo Technology showed positive performance with gains of 2.40% and 1.36% respectively, alongside significant net inflows [2]